Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

MAFPMethoxy arachidonyl fluorophosphonate

Irreversible FAAH inhibitor (IC50 1 to 3 nM); it also inhibits phospholipases A2 and binds CB1 (IC50 20 nM).

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₁H₃₆FO₂P

CID 10429254

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
370.50 g/mol

Updated on

In plain terms

MAFP permanently blocks the enzyme that destroys anandamide. It has been used to study the role of that enzyme, but it also binds the CB1 receptor and inhibits other enzymes, which makes it a powerful but imprecise tool. It has been studied only in cells and tissues; no study in humans was found.

Receptors and activity

Target network

FAAHInhibitorIC50 = 3 nMcovalent inhibition of anandamide amidohydrolase partially purified from N18TG2 cells (mouse), RBL-1 cells (rat) and pig brain: IC50 of 1 to 3 nM depending on the preparation (upper value retained); about 800-fold more potent than arachidonyl trifluoromethyl ketone on rat brain homogenates (Deutsch 1997)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to MAFP: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MAFP.

Brain, side view
Body, front view
Blood

FAAHFAAH found in 7 regions of the body

  1. CortexpresentCortical pyramidal neurons1
  2. Basal gangliapresentStriatal neurons1
  3. HypothalamuspresentPresent in hypothalamic nuclei1
  4. CerebellumpresentPurkinje cells and cerebellar layers1
  5. BrainstempresentInferior olivary nuclei1
  6. Adipose tissuepresentExpressed in mature adipocytes2
  7. BonepresentPresent on osteoclasts3

Cited values

  1. FAAHInhibitorIC50 = 3 nM75 out of 100

    De Petrocellis et al., Biochem Biophys Res Commun 1997 (new tab) · covalent inhibition of anandamide amidohydrolase partially purified from N18TG2 cells (mouse), RBL-1 cells (rat) and pig brain: IC50 of 1 to 3 nM depending on the preparation (upper value retained); about 800-fold more potent than arachidonyl trifluoromethyl ketone on rat brain homogenates (Deutsch 1997)

  2. CB1Binding (function not established)IC50 = 20 nM62 out of 100

    Deutsch et al., Biochem Pharmacol 1997 (new tab) · [3H]CP-55940 displacement (IC50 of 20 nM versus 40 nM for anandamide); preparation not specified in the abstract; irreversible binding; functional effect not established

  3. iPLA2 (calcium-independent phospholipase A2)InhibitorIC50 = 500 nM · mouse38 out of 100

    Lio et al., Biochim Biophys Acta 1996 (new tab) · P388D1 macrophage enzyme: half-maximal inhibition at 0.5 µM after 5 min preincubation at 40 °C; irreversible inhibition

  4. cPLA2 (phospholipase A2 cytosolique de 85 kDa)Inhibitorno measured value cited

    Irreversible active-site-directed inhibitor, recalled as such by Lio et al. 1996; no value in the abstract

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

MAFP (methoxy or methyl arachidonyl fluorophosphonate) is an organophosphorus compound built around an arachidonic chain recognised by endocannabinoid enzymes, carrying a reactive fluorophosphonate. First known as an irreversible inhibitor of phospholipases A2 (Lio et al. 1996), it was described in 1997 as a very potent inhibitor of anandamide amidase: about 800 times more potent than arachidonyl trifluoromethyl ketone in rat brain homogenates (Deutsch et al. 1997) and with an IC50 of between 1 and 3 nM, making it the most potent inhibitor described at the time (De Petrocellis et al. 1997). The same Deutsch publication nonetheless flagged its limit: it also binds the CB1 receptor, which it occupies irreversibly with an IC50 of 20 nM, better than anandamide (40 nM). Lio and colleagues had further shown that it also inhibits calcium-independent phospholipase A2 (IC50 0.5 µM) and does not discriminate between the two phospholipases A2, advising caution when it is used in intact cells. A tool meant to isolate the effect of raised anandamide therefore acts on other targets at the same time, which makes results delicate to interpret. These studies concern enzyme and cell preparations; no study in humans was found.

History

Source
An entirely synthetic compound with no natural occurrence found in the sources consulted. It is described as a biochemical research reagent; no human or veterinary use was found.

Origin

Research tool

No biological pathway: MAFP is a synthetic compound, a fluorophosphonate with an arachidonic chain, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Methoxy arachidonyl fluorophosphonate (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Methoxy arachidonyl fluorophosphonate
IUPAC name
(5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene
Other names
MAFP · methyl arachidonyl fluorophosphonate

Identifiers

Formula
C₂₁H₃₆FO₂P
InChIKey
KWKZCGMJGHHOKJ-ZKWNWVNESA-N
SMILES
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCP(=O)(OC)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.